A new study published in Clinical Therapeutics by Boyar and colleagues analyzes mycotoxin compliance testing data across cannabis flower and concentrates in U.S. regulated markets. The analysis surveys how often samples exceed action limits set by state regulators and how those rates differ between unprocessed flower and concentrated products.
Mycotoxin contamination — including aflatoxins and ochratoxin A — can persist in stored plant material when post-harvest moisture and temperature controls are inadequate. State-level testing programs are one of the only systematic windows into how often these toxins reach consumer products.
For patients managing chronic inflammatory illness, the data is a reminder that ingestion exposure to mycotoxins is not limited to obvious sources like water-damaged buildings; it can also come through routinely consumed products, and regulatory thresholds vary by jurisdiction.